Phase 1 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 20 years or older
- People who have been diagnosed through a tissue biopsy with a specific type of head and neck cancer (squamous cell carcinoma), or who have suspicious lymph nodes that may indicate cancer spread, at a certain stage of disease, and who have not yet had surgery for this condition
- People whose treating doctor has determined that lymph node removal surgery is needed within 8 weeks, based on standard care at the trial site
- People who are not currently breastfeeding
- People who are able to understand and are willing to sign a written consent form
- People who are able to follow the study's procedures and requirements
Who may not be able to join:
- People who have a medical reason why they cannot have an MRI scan
- People with a history of serious allergic reactions, or a known allergy to ingredients found in the contrast agents used in this study (including gadolinium-based agents, SPIO particles, or iodine-based contrast agents)
- People who had a gadolinium-enhanced MRI scan within 7 days before enrolling in the trial
- People who took part in another imaging-related clinical trial within 30 days before enrolling
- People with active widespread infections, significant active heart conditions, active stomach or intestinal ulcers, or other health conditions that may seriously affect how the study contrast agent works in the body
- People with kidney disease or reduced kidney function
- People with liver or spleen disease or problems, identified through other scans (such as CT or MRI) or lab results
- People with an active hepatitis B or hepatitis C infection
- People with bone marrow disorders or a history of bone marrow transplant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pei-Jen Lou, MD., PhD, National Taiwan University Hospital
Phone: +886-35910360
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity and Specificity of MPB-2043 Enhanced MRI in Detecting Lymph Node Metastasis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.